and the divestment of the thrombosis portfolio is “not material”, GSK said. A series of trial results announced last week showed GSK’s respiratory products are facing tough competition.

In contrast to respiratory drugs ... % of non-GAAP net income (at the midrange relative to peers based on GSK’s product portfolio having average exposure to future potential litigation).

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and ... be in four key franchises: Respiratory, HIV (ViiV Healthcare ...

In contrast to respiratory drugs ... % of non-GAAP net income (at the midrange relative to peers based on GSK’s product portfolio having average exposure to future potential litigation).

The growth of these products comes from strong patient demand. These two long-acting medicines contributed more than 50% of the total HIV growth and now account for 20% of HIV sales. In 2025, GSK ...

Sales of the respiratory ... product demand across all regions. Oncology sales rose 72%, driven by strong patient demand for Jemperli and Ojjaara. Jemperli added £149 million to GSK’s top ...